MOTS-C/Humanin Blend Research & Listing Availability
Current MOTS-C/Humanin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
Current MOTS-C/Humanin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
About MOTS-C/Humanin Blend
Pre-clinical / research-onlyAlso known as: MOTS-c + Humanin · MDP BlendThe MOTS-C/Humanin Blend combines two mitochondrial-derived peptides — MOTS-c and humanin — in one research product, most often sourced for metabolic and cellular-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone MOTS-c and Humanin entries for full per-component pharmacology.[1][2]
What to check before you buy MOTS-C/Humanin Blend:
- A third-party COA that confirms BOTH peptides by mass spec — MOTS-c and humanin — at ≥98% purity by HPLC, since a blend can ship off-ratio or missing one component.
- A COA dated within the last 6–12 months that matches the exact vial size, batch, and stated mg-per-peptide ratio you are buying.
- Accurate vial fill for each peptide: off-ratio or under-filled blend vials are a common failure mode that throws off reconstitution math.
No peer-reviewed clinical or pre-clinical study has evaluated this specific blend or its dose ratio. The single-component literature for MOTS-c (metabolic, insulin-sensitivity, healthspan) and humanin (neuroprotection, anti-apoptotic, insulin-sensitivity) is reviewed in their respective entries.[1][2][3][4] No registered ClinicalTrials.gov trial exists for any MDP blend.[5]
Regulatory: Not FDA-approved. No clinical or pre-clinical study of the specific blend. Research-grade material only — each component is investigational with rodent and observational data only.
MOTS-C/Humanin Blend: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how MOTS-C/Humanin Blend works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
This is a convenience research blend, not a clinically validated combination product, so the most honest framing is to refer the reader to the per-component entries: see the standalone MOTS-c deep dive for the AMPK-activation, folate-methionine-cycle, and nuclear-translocation-under-metabolic-stress mechanisms,[1][4] and the standalone Humanin deep dive for the Bax-binding intracellular anti-apoptotic arm and the CNTFR/WSX-1/gp130 extracellular signalling arm.[2][3] The biological rationale for combining them is the "mitochondrial-derived peptide signalling network" framing developed by the Cohen lab and others: MOTS-c and humanin (with the SHLP family) are co-expressed from the mitochondrial genome, both decline with age in humans and primates, and they appear to act on complementary axes (MOTS-c primarily metabolic/AMPK; humanin primarily cytoprotective/anti-apoptotic).[1][2][3] **There is no published study of the specific blend, no characterised dose ratio, no pharmacokinetic data for the combination, and no demonstration of synergy beyond what either peptide produces alone.**
Active research areas
- No blend-specific research
- Single-component evidence (cross-reference)
- No human clinical programNo registered ClinicalTrials.gov trial of MOTS-c + humanin combination or of any MDP blend.[5]
Open questions & leading hypotheses (1)
- Hypothesis: Co-administration of MOTS-c and humanin produces additive or synergistic effects beyond either peptide alone.Evidence: Both peptides decline with age and act on complementary axes, providing a biological rationale for combination.[1][2][3] Counter-evidence: no published study has tested the combination in any model, no synergistic mechanism has been characterised, and the blend ratio is set by vendor convention rather than any pharmacology data; until a controlled comparison vs. either peptide alone exists, the additive-benefit claim is unsupported.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides, MOTS-c/humanin blends are framed as a "mitochondrial peptide stack" with typical subcutaneous dosing of 5–10 mg combined, 2–3× per week, often on a 4–8 week cycle.[6] Users report subjective improvements in energy and recovery, similar to standalone MOTS-c protocols. **All reports are anecdotal, no blend-specific human or animal data exist, the dose ratio is vendor convention rather than evidence-based, and neither component is FDA-approved.**
Sources & references (6)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443–454. · PMID: 25738459 link
- [2]Hashimoto Y et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ (humanin). PNAS 2001;98:6336–6341. · PMID: 11371646 link
- [3]Yen K et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 2020;12:11185–11199. · PMID: 32575074 link
- [4]Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab 2018;28:516–524.e7. · PMID: 29983246 link
- [5]ClinicalTrials.gov search "MOTS-c humanin", accessed May 2026 — no registered trial of the blend. link
- [6]Community report — r/Peptides MOTS-c/humanin blend threads (subreddit), accessed May 2026. link
MOTS-C/Humanin Blend Calculator Input Observations
In lifetime MOTS-C/Humanin Blend calculator inputs, 5mg is the most frequent entered amount (18 of 77 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (6 of 26 lifetime frequency responses, across entered amounts). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.
About MOTS-C/Humanin Blend
The MOTS-C/Humanin Blend combines two mitochondrial-derived peptides — MOTS-c and humanin — in one research product, most often sourced for metabolic and cellular-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone MOTS-c and Humanin entries for full per-component pharmacology.
MOTS-C/Humanin Blend is a blend of Humanin and MOTS-c, so a COA has to confirm each component separately — a single purity figure for the mixture is not enough. Its reported half-life is ~4 hours (MOTS-c-driven). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
Frequently Asked Questions: MOTS-C/Humanin Blend
Are current MOTS-C/Humanin Blend offers available?
Current MOTS-C/Humanin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
What can I check if MOTS-C/Humanin Blend listings become available?
Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.
Does research activity establish current MOTS-C/Humanin Blend availability?
No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.